- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
Original 110-patient enrollment target achieved ahead of the Company’s end-of-September guidance. The MAVERIC Steering Committee recommends expanding enrollment to up to 150 patients to capture sufficient events for a robust [...] The post Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™’s Efficacy appeared first on Cardiol Therapeutics.
Proceeds strengthen balance sheet ahead of pivotal Phase III MAVERIC trial data readout in recurrent pericarditis and extends cash runway into H1 2028. Toronto, ON – September 16, 2026 – [...] The post Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds appeared first on Cardiol Therapeutics.
TORONTO, Ontario — September 10, 2026 — Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart [...] The post Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission appeared first on Cardiol Therapeutics.
Toronto, ON – September 9, 2026 – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart [...] The post Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference appeared first on Cardiol Therapeutics.
HFpEF affects more than half of all heart failure patients globally and has resisted every therapeutic approach the field has applied to it. The post Inflammation and the Heart: Why the Field Is Asking a Different Question appeared first on Cardiol Therapeutics.
Toronto, ON, August 5, 2026 – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, [...] The post Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity’s 46th Annual Growth Conference appeared first on Cardiol Therapeutics.
Peer-reviewed JAHA publication strengthens the foundation for Cardiol’s pivotal Phase III MAVERIC trial as enrollment nears completion. Toronto, ON, July 14, 2026 – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) [...] The post Cardiol Therapeutics’ Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association appeared first on Cardiol Therapeutics.
Toronto, ON, July 9, 2026 – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, [...] The post Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit appeared first on Cardiol Therapeutics.
Toronto, ON – June 25, 2026 – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart [...] The post Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders appeared first on Cardiol Therapeutics.
Toronto, ON – June 23, 2026 – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart [...] The post Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT appeared first on Cardiol Therapeutics.
